Latest 30 News in the Life Sciences Industry
PR Newswire Association LLC.
LIGHT AI ANNOUNCES COMPANY-FUNDED FIELD STUDY IN NEW ZEALAND FOR QUICKSCAN™ STREP A PLATFORM
16 Jun 2026
GlobeNewswire
EURneffy 1 mg approved in the UK as the first and only needle-free adrenaline treatment for young children (aged 4 and older, 15–30 kg) at risk of anaphylaxis
15 Jun 2026
PR Newswire Association LLC.
Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026
15 Jun 2026
GlobeNewswire
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
15 Jun 2026
GlobeNewswire
Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)
15 Jun 2026
PR Newswire Association LLC.
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
14 Jun 2026
PR Newswire Association LLC.
MGI Tech Showcases Expanding Genomics Ecosystem at ESHG 2026 with New IVD Partnering Program and OEM Collaborations
13 Jun 2026
PR Newswire Association LLC.
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
13 Jun 2026
GlobeNewswire
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
13 Jun 2026
GlobeNewswire
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
13 Jun 2026
PR Newswire Association LLC.
AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
12 Jun 2026
GlobeNewswire
Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2026 MedTech Innovation Spotlight
12 Jun 2026
GlobeNewswire
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
12 Jun 2026
GlobeNewswire
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
11 Jun 2026
PR Newswire Association LLC.
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies
11 Jun 2026
PR Newswire Association LLC.
IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
11 Jun 2026
GlobeNewswire
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
11 Jun 2026
GlobeNewswire
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
11 Jun 2026
PR Newswire Association LLC.
Sobi to present new clinical and real-world data at EHA 2026 in Stockholm
11 Jun 2026
PR Newswire Association LLC.
Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
10 Jun 2026
PR Newswire Association LLC.
First Patient Enrolled in New Study Assessing early prediction of flares in Atopic Dermatitis by Castle Biosciences in Collaboration with SciBase
10 Jun 2026
PR Newswire Association LLC.
HERVolution Therapeutics Demonstrates Preclinical Proof-of-Concept for Insulin Sensitization Immune Therapy in Metabolic Disease and Announces Exclusive License Agreement with the University of Copenhagen
10 Jun 2026
Latest News All News
Upcoming Events All Events
- June 2026
- San Diego: RESI San Diego 2026
- San Diego: BIO 2026
- July 2026
- Taipei: BIO Asia-Taiwan